BCL6

BCL6 (B 细胞淋巴瘤 6) 是一种锌指转录抑制因子,在 B 细胞生发中心 (Germinal Center, GC) 反应中发挥关键作用。BCL6 可通过抑制 DNA 损伤检查点基因 (ATR、CHEK1、TP53),降低细胞对 DNA 损伤的应答,使 B 细胞能够在生发中心的高突变环境下持续增殖。同时,BCL6 也可通过下调细胞增殖抑制因子 (CDKN1A、PTEN) 促进 B 细胞增殖,并抑制终末分化相关基因 (IRF4、PRDM1),防止 B 细胞过早分化为浆细胞,以维持生发中心反应。此外,BCL6 还能竞争性抑制炎症信号通路 (STAT3、NF-κB),降低免疫系统的过度激活,起到抗炎作用。
BCL6 稳定表达依赖于正反馈机制,如 p300 通过抑制 HSP90 乙酰化来稳定 BCL6,而 EZH2 通过 H3K27 甲基化 进一步增强 BCL6 的转录抑制功能。 在弥漫性大 B 细胞淋巴瘤 (DLBCL)、B 细胞急性淋巴细胞白血病 (B-ALL)、慢性粒细胞白血病 (CML)、乳腺癌和非小细胞肺癌 (NSCLC) 等多种肿瘤中,BCL6 通过基因突变、染色体易位或共抑制因子异常维持癌细胞存活。因此,针对 BCL6 BTB 结构域的抑制剂可有效阻断其与共抑制因子的结合,从而抑制肿瘤生长,为恶性肿瘤的研究提供了新策略[1]。

BCL6 (B-cell lymphoma 6) is a zinc-finger transcriptional repressor that plays a crucial role in the germinal center (GC) reaction of B cells. BCL6 can promote the continuous proliferation of B cells in the highly mutagenic GC environment by suppressing DNA damage checkpoint genes (ATR, CHEK1, TP53), thereby reducing the cellular response to DNA damage. Additionally, BCL6 facilitates B cell proliferation by downregulating cell cycle inhibitors (CDKN1A, PTEN) and prevents premature differentiation into plasma cells by repressing terminal differentiation genes (IRF4, PRDM1), ensuring the maintenance of the GC reaction. Furthermore, BCL6 competitively inhibits inflammatory signaling pathways (STAT3, NF-κB), thereby reducing excessive immune activation and exerting an anti-inflammatory effect.
The stable expression of BCL6 relies on positive feedback mechanisms, such as p300-mediated inhibition of HSP90 acetylation, which stabilizes BCL6, and EZH2-catalyzed H3K27 methylation, which further enhances BCL6's transcriptional repression. In various cancers, including diffuse large B-cell lymphoma (DLBCL), B-cell acute lymphoblastic leukemia (B-ALL), chronic myeloid leukemia (CML), breast cancer, and non-small cell lung cancer (NSCLC), BCL6 contributes to cancer cell survival through genetic mutations, chromosomal translocations, or dysregulation of co-repressors. Therefore, inhibitors targeting the BTB domain of BCL6 can effectively block its interaction with co-repressors, thereby suppressing tumor growth and providing a novel therapeutic strategy for malignant tumors[1].

共 4种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
Glycochenodeoxycholic acid sodium salt
甘氨鹅脱氧胆酸钠; Chenodeoxycholylglycine sodium salt; Sodium glycochenodeoxycholate

Glycochenodeoxycholic acid sodium salt(Chenodeoxycholylglycine)是肝脏中由甘氨鹅脱氧胆酸和甘氨酸产生的一种相对有毒的胆盐,它通过抑制人正常肝细胞中溶酶体蛋白水解并升高溶酶体 pH 来抑制自噬体(Autophagosome)形成和损害溶酶体功能,从而导致人肝细胞凋亡(Apoptosis),并通过激活 STAT3 信号通路诱导肝癌细胞的干细胞性质和化疗耐药性,有望用于胆汁淤积症、肝癌和原发性硬化性胆管炎(PSC)领域的研究。

16564-43-5
Activator
98.51%
甘氨鹅脱氧胆酸钠
Glycochenodeoxycholic acid sodium salt (Standard)
甘氨鹅脱氧胆酸钠 (标准品); Chenodeoxycholylglycine sodium salt (Standard); Sodium glycochenodeoxycholate (Standard)

Glycochenodeoxycholic acid sodium salt (Standard) 是 Glycochenodeoxycholic acid sodium salt 的分析标准品,本产品用于研究及分析应用,而 Glycochenodeoxycholic acid sodium salt (Chenodeoxycholylglycine) 是肝脏中由甘氨鹅脱氧胆酸和甘氨酸产生的一种相对有毒的胆盐,并通过抑制人正常肝细胞中溶

16564-43-5
Activator
99.75%
甘氨鹅脱氧胆酸钠 (标准品)
Glycochenodeoxycholic acid
甘氨鹅脱氧胆酸; Chenodeoxycholylglycine

Glycochenodeoxycholic acid(Chenodeoxycholylglycine)是肝脏中由甘氨鹅脱氧胆酸和甘氨酸产生的一种相对有毒的胆盐,它通过抑制人正常肝细胞中溶酶体蛋白水解并增加溶酶体 pH 来抑制自噬体(Autophagosome)形成和损害溶酶体功能,从而导致人肝细胞凋亡(Apoptosis),并通过激活 STAT3 信号通路诱导肝癌细胞的干细胞性质和化疗耐药性,有望用于胆汁淤积症、肝癌和原发性硬化性胆管炎(PSC)领域的研究。

640-79-9
Activator
99.81%
甘鹅去氧胆酸杂质24
Glycochenodeoxycholic acid (Standard)
甘氨鹅脱氧胆酸 (标准品); Chenodeoxycholylglycine (Standard)

Glycochenodeoxycholic acid (Standard) 是 Glycochenodeoxycholic acid 的分析标准品,用于研究及分析应用;Glycochenodeoxycholic acid (Chenodeoxycholylglycine) 是肝脏中由甘氨鹅脱氧胆酸和甘氨酸产生的一种相对有毒的胆盐,通过抑制人正常肝细胞中溶酶体蛋白水解并增加溶酶体 pH 来抑制自噬体 (Autophagosome) 形成。

640-79-9
Activator
99.77%
甘鹅去氧胆酸杂质24 (标准品)

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础